Cancer

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Act1 (Adaptor for IL-17 receptors) increases the expression of tumor suppressors genes, such as PDCD4, CADM1, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 30/October/2018, 11.01 pm

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Act1 (Adaptor for IL-17 receptors) increases the expression of tumor suppressors genes, such as PDCD4, CADM1, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 30/October/2018, 11.01 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Mibolerone (Trade name: Cheque drops and Matenon), an anabolic-androgenic steroid, increases the expression of tumor suppressors genes, such as PTPN14, RB1, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 30/October/2018, 10.53 pm

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Mibolerone (Trade name: Cheque drops and Matenon), an anabolic-androgenic steroid, increases the expression of tumor suppressors genes, such as PTPN14, RB1, p53,  p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 30/October/2018, 10.53 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Awakening the sleeping/cancer-protecting angels in mutant p53 human tumors: Sulindac (brand name: Clinoril), a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of acute and chronic inflammatory conditions,  increases the expression of tumor suppressors genes, such as BTG2, TIMP3,  p53, TAp63, TAp73, INK4a, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 30/October/2018, 6.53 pm

Awakening the sleeping/cancer-protecting angels in mutant p53 human tumors: Sulindac (brand name: Clinoril), a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of acute and chronic inflammatory conditions,  increases the expression of tumor suppressors genes, such as BTG2, TIMP3,  p53, TAp63, TAp73, INK4a, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 30/October/2018, 6.53 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Awakening the sleeping/cancer-protecting angels in mutant p53 human tumors: Sulindac (brand name: Clinoril), a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of acute and chronic inflammatory conditions,  increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 26/October/2018, 11.14 pm

Awakening the sleeping/cancer-protecting angels in mutant p53 human tumors: Sulindac (brand name: Clinoril), a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of acute and chronic inflammatory conditions,  increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 26/October/2018, 11.14 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as HNF4α, CADM1/2, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 22/October/2018,11.18 pm

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as HNF4α, CADM1/2, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 22/October/2018,11.18 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows that “Prostaglandin E1 and…

read more

Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as TIMP3, PDCD4, p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 22/October/2018, 10.13  pm

Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as TIMP3, PDCD4, p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 22/October/2018, 10.13  pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more